The effect of olaparib on the PD-1/PD-L1 signaling pathway in platinum-sensitive recurrent BRCA-mutant ovarian cancer patients
10.3969/j.issn.1673-4130.2024.15.008
- VernacularTitle:奥拉帕利对铂敏感复发BRCA突变卵巢癌患者PD-1/PD-L1信号通路的影响
- Author:
Jing CHEN
1
;
Nan TANG
;
Yuanyuan WU
;
Yuan TIAN
;
Tong LIU
;
Runpu LI
Author Information
1. 保定市第二中心医院肿瘤科,河北保定 072750
- Keywords:
ovarian cancer;
platinum-sensitive;
olaparib;
breast cancer susceptibility gene
- From:
International Journal of Laboratory Medicine
2024;45(15):1834-1838
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of olaparib and platinum-based regimen on tumor angiogen-esis-related factors and programmed death-1(PD-1)/programmed death-ligand 1(PD-L1)signaling pathway in platinum-sensitive relapsed breast cancer susceptibility gene(BRCA)mutation ovarian cancer(OC)pa-tients.Methods A retrospective analysis was conducted on 95 platinum-sensitive recurrent BRCA mutation OC patients in a hospital from May 2018 to May 2020.The patients were divided into two groups based on their treatment regimen:the control group(47 cases)received paclitaxel plus platinum therapy,and the obser-vation group(48 cases)received olaparib tablets.The efficacy,safety,tumor angiogenesis-related factors[an-giogenin-2(Ang-2),vascular endothelial growth factor(VEGF),stromal cell-derived factor-1α(SDF-1α)],pe-ripheral blood CD4+T cells PD-1,PD-L1 levels were compared between the two groups.Results DCR in ob-servation group was higher than that in control group,the difference was statistically significant(P＜0.05).There was no significant difference in the incidence of nausea,fatigue and fatigue,vomiting,anemia,diarrhea,leukopenia,neutropenia and anorexia between the observation group and the control group(P＞0.05).The serum levels of VEGF,Ang-2 and SDF-1α in the observation group were lower than those in the control group after 3 and 6 cycles of treatment,and the differences were statistically significant(P＜0.05).The levels of periph-eral blood CD4+T cells PD-1 and PD-L1 in the observation group were lower than those in the control group at 3 and 6 cycles of treatment,and the difference was statistically significant(P＜0.05).Conclusion Olaparib is used in platinum-sensitive relapsed BRCA mutation OC patients to regulate the PD-1/PD-L1 signaling pathway,re-duce the levels of tumor angiogenesis-related factors,and improve therapeutic efficacy.
